DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* FLAMEL TECHNOLOGIES *


 

1990 - Rhône-Alpes
Venissieux
(near Lyon)
www.flamel.com

 

Delivery, Drugs
(also, Design, Devices)
Key words: Polymer encapsulation, Interferon, Micropump, Medusa, Drug-protein delivery, Long Action
Mission: to improve the therapeutic characteristics, safety profile and ease of use of a wide variety of existing drugs, by using proprietary drug delivery platforms, Medusa for therapeutic proteins and peptides and Micropump for small molecules, with expertise in polymer chemistry
Clients: Pharmaceutical industry (own development up to pre-registration), Agrochemical industry
info@flamel.com

Age: 26 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Start-up |
Managing Dir.-CEO: Anderson (Michael S.) [ex-Éclat Pharmaceuticals, KV Pharmaceutical, Ther-Rx Corporation, Schein, A.H. Robins Company]
Sc.Dir.-CSO: Meyrueix (Rémi) [Ph.D., Eng. Physics, ex-Rhône Poulenc Santé] & Castan (Catherine) [Ph.D.]
Oper.Dir.-COO: Jorda (Raphaël) [Ph.D., Eng. chemistry, ex-Rhône Poulenc Santé]
Fin.Dir.-CFO: Crouzet (Siân) [ex-McCormik, Ernst & Young]
BusDev: Lisi (Steven A.) [ex-Deerfield Mgt, Panacea Asset Mgt, Millenium Partners]
Strat.Comm.Dir.: Mosseri Marlio (Charles)
Financers (Hist.): Public (Nasdaq)

Turnover (M€) : 23.8 (2008), 18.7 (2006)
Total funding (M€) : n.a.
Last funding (M€) : n.a.
Focus : Multiple
Position : Trade
Company confirm : neutral

 

History
DATEMILESTONETYPETIME
2012 .04 Nomination : Michael S. Anderson as CEO (ex-CEO of acquired Éclat), replacing Stephen H. Willard ORGN [21 years]
2012 .03 Acquisition of Éclat Pharmaceuticals (USA),incorporated in Flammel US inc. ACQ+ [21 years]
2011 .11 Supply Agreement with GlaxoSmithKline for Coreg CR Microparticles, using Flamel's Micropump technology, with upfront payment of 1.2 M€ MKTG [21 years]
2011 .10 Partnering R&D agreement with Eagle Pharmaceuticals (USA) on Medusa-based hydrogel depot formulation for Eagle's small molecule antibiotic, tigecycline R&D [21 years]
2011 .06 Partnering research agreement with Digna Biotech (Spain) for multiple products R&D [20 years]
2011 .04 Licensing-out of Micropump to an undisclosed company, for pain management, with upfront payment of 3 M€ LICOUT [20 years]
2010 .10 Partnering research agreement with Merck Serono for an extended release formulation of interferon beta-1a using the Medusa platform R&D [20 years]
2009 .12 Clinical trial (phase IIa) of IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection (beginning) CLIN [19 years]
2009 .07 Partnering research agreement with Baxter to formulate Longer Acting Forms of Blood Clotting Factors R&D [18 years]
2009 .03 Financing : € 2.9 Millions ($4 Million) from GlaxoSmithKline (GSK) as a milestone pursuant to the Micropump license agreement for Coreg CR RFIN [18 years]
2007 .12 Partnering research agreement with Merck Serono R&D [17 years]
2006 .10 Registration : FDA approval of Coreg (carvedilol S.R), licensed to GSK MKTG [16 years]
2005 .06 Nomination : Stephen H. Willard as CEO (from CFO in 2000), replacing founder Gérard Soula, after a coup by hedge funds ORGN [14 years]
2003 .11 Licensing-out of Basulin to BMS, with upfront payment of 18 M€ (20.0 MUS$) LICOUT [13 years]
2003 .10 Public offering (Nasdaq) : 56 M€ (62.1 MUS$) PBO [13 years]
2002 .07 Licensing-out of Augmentin delivery-improved to GSK, with upfront payment of 1.3 M€ LICOUT [11 years]
2000 .03 Round-financing : 12.8 M€, by Biotechnology Value Fund, Alta Biopharma, Chase Capital Partners RFIN [9 years]
1999 .12 Licensing-out of Basulin to Novo Nordisk, with upfront payment of 5 M€ and milestones of 37 M€ (rights re-acquired in 2002) LICOUT [9 years]
1996 .12 Listing on Nasdaq : 30 MUS$ (about 23.7 M€) PBO [6 years]
1990 .08 Company founded by Gérard Soula [CEO, ex-Rhône Poulenc R&D], Jean Deléage [Alta Partners, as CEO, Supélec, died in 2011] ORGF [0 year]

Actualisation / Updating: 1-Nov-2012

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende